Cyclophosphamide pulse therapy for refractory rheumatic diseases.
نویسندگان
چکیده
منابع مشابه
[Cyclophosphamide pulse therapy for refractory rheumatic diseases].
We studied the efficacy of cyclophosphamide pulse therapy (CYP) for refractory rheumatic diseases except for lupus nephritis. Thirty-five patients were included in all, that is 9 patients with systemic lupus erythematosus (SLE), 10 with rheumatoid arthritis (RA), 7 with polymyositis/dermatomyositis (PM/DM), 2 with progressive systemic sclerosis (PSS), 2 with anti-phospholipid antibody syndrome ...
متن کاملPulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura.
Autoimmune thrombocytopenic purpura (AITP) is generally a chronic disorder in affected adults. Twenty-five percent of these patients will become refractory to routine therapy (corticosteroids and splenectomy), as well as most other available agents. Intravenous pulse cyclophosphamide therapy was used to treat 20 patients with severe refractory AITP who had previously failed to achieve a sustain...
متن کاملAnti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases.
OBJECTIVES We aim to report the efficacy and safety of rituximab (RTX) in patients diagnosed with juvenile systemic lupus erythematosus (JSLE) or juvenile idiopathic arthritis (JIA) refractory to conventional treatment. METHODS A retrospective review was made of all medical records of patients with JSLE or JIA treated with RTX between January 2009 and January 2015 in the Pediatric Rheumatolog...
متن کاملUsefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases.
BACKGROUND Interstitial lung diseases (ILDs) are a group of disorders characterised by progressive lung function decline. Stabilisation of lung function under intermittent i.v. cyclophosphamide was shown in patients suffering from systemic sclerosis, yet data in ILD patients are scarce. OBJECTIVES To retrospectively evaluate the usefulness of cyclophosphamide pulse therapy in ILD. METHODS W...
متن کاملPrednisone pulse therapy for refractory myeloma.
The utility of vindesine and a frequent prednisone schedule was evaluated in 70 patients with refractory myeloma. No patient responded to vindesine alone, but about one-fourth achieved significant tumor reductions from intermittent high-dose prednisone, either alone or in combination with vindesine. Forty-seven percent responded when prednisone pulses were combined with vincristine and doxorubi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Immunology
سال: 1997
ISSN: 0911-4300,1349-7413
DOI: 10.2177/jsci.20.152